Search

Quaternium-15

Sensitivity to Quaternium-15 may be identified with a clinical patch test. … In 2005, Quaternium-15 was named in the top 15 most frequently positive allergens identified in patch tests by the North American Contact Dermatitis Group (NACDG)[A34326].

Trimethaphan

A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery.

Barnidipine

It is available in modified-release oral tablets under the brand name Vasexten to be taken once daily in the morning. … after a 1-year and 2-year follow-up period in 91% of the patients who had an initial response to the drug [A7842].

Lepirudin

[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine … [A3, L41539] HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and platelet factor 4.

Sodium aurothiomalate

It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis.

Nicorandil

It is shown to dilate normal and stenotic coronary arteries and reduces both ventricular preload and afterload [A20325]. … Nicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan.

Linoleic acid

Equine Botulinum Neurotoxin G Immune FAB2

It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes G in adults and pediatric patients.

Equine Botulinum Neurotoxin D Immune FAB2

It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes D in adults and pediatric patients.

CX-046684

It is the active ingredient of the 2024-2025 formulation of Moderna's Spikevax vaccine.[L40074] … CX-046684 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage KP.2.